🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to scientists.

An International Health Concern

The sexually transmitted infection are escalating worldwide, with figures suggesting more than 82 million new cases per year. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, escalating drug resistance and the highly restricted treatment choices currently available.”

Public health authorities are increasingly worried about the rise in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This authorization represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Results and Global Access

As per data published in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the current standard treatment, which combines two antibiotics. The trial included nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Doctors on the front lines have shared hope. Having a single-dose, oral treatment of this kind is described as a "critical tool" for public health efforts. This is considered essential to alleviate the strain of the infection for individuals and to halt the transmission of untreatable gonorrhoea globally.